What is the significance of this filing being an amendment (10-Q/A)?

An amended filing (10-Q/A) means that Amgen previously filed a 10-Q for the period and is now submitting a revised version. This could be due to corrections of errors, the addition of previously omitted information, or a response to regulatory inquiries. Investors should carefully review the reasons for the amendment and any changes made compared to the original filing.

What key financial information would investors look for in this 10-Q filing?

Investors would typically seek information on Amgen's revenue growth, profitability (net income and earnings per share), operating expenses, cash flow from operations, and any significant changes in financial condition. Details on sales performance of key products like Epogen and Neupogen would also be crucial.

What non-financial information is important in a 10-Q filing for a biotech company like Amgen?

For a biotechnology company, non-financial information is critical. Investors would look for updates on the progress of their drug pipeline, clinical trial results, regulatory submissions and approvals (e.g., from the FDA), any patent litigation, and strategic partnerships or acquisitions. Information on research and development expenditures is also a key indicator of future growth potential.

Where can I find the actual financial data for Amgen's Q1 1995?

The provided text is only a directory listing of the filing's location on the SEC's EDGAR system. To access the complete financial statements and management discussion, you would need to navigate to the SEC's EDGAR database and search for Amgen Inc. (AMGN) filings, specifically the 10-Q/A filed on or around May 15, 1995, with the period ending March 30, 1995.

AMGN 10-Q Quarterly Report Q1 FY1995 — Revenue, Net Income, EPS

Summary

Amgen Inc. filed an amended quarterly report (10-Q/A) for the period ending March 30, 1995. While the provided filing content is primarily the directory listing of the archived document and not the financial statements themselves, it indicates a significant filing from a major biotechnology company during that era. Investors would typically look for details on revenue, earnings, product pipeline progress, clinical trial results, and any significant corporate developments or regulatory news. Given this is an amendment, it suggests a previous filing may have required correction or additional disclosure, which would be critical for understanding the company's true financial and operational standing at that time.

Key Highlights

1Amgen Inc. filed an amended 10-Q report for the quarter ending March 30, 1995.
2The filing is an amendment (10-Q/A), indicating a prior filing may have been corrected or supplemented.
3The period covered is the first quarter of 1995.
4Amgen is a prominent biotechnology company, making its quarterly updates closely watched by investors.
5Without the actual financial statements, specific operational and financial highlights cannot be determined from the provided text.
6Investors would need to review the full 10-Q/A filing for details on revenue, expenses, product performance, and future outlook.

AMGEN INC Quarterly Report (Amendment) for Q1 Ended Mar 31, 1995

Summary

Key Highlights

Frequently Asked Questions